Co-authors Dr. William Sherk and Dr. Jadranka Stojanovska, both from the University of Michigan Health System, developed clinical decision rules to determine which patients with suspected pulmonary embolism would benefit from further diagnostic workup, such as pulmonary CTA. They found that overall, CTA is overused for screening as opposed to diagnostic examination, which leads to increased financial costs and patient exposure to radiation and contrast media (AJR, March 2017, Vol. 208:3, pp. W60-W70).
Clinical decision support could help, they concluded.
"The qualities of pulmonary CTA make it desirable to clinicians as a test for suspected PE," they wrote. "As with other diagnostic tests, however, the post-test probability of pulmonary CTA hinges on pretest clinical assessment. Validated clinical decision rules and integrated CDS systems can influence the appropriate use of pulmonary CTA, but further investigation is required to define the most successful means of integration into clinical practice."If you like this content, please share it with a colleague!
Copyright © 2017 AuntMinnie.com